Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00397696 · ClinicalTrials.gov registry record · Phase 2
Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons Disease
A Phase 2 study, sponsored by Institute for Neurodegenerative Disorders.
- Completed
- Registry status
- Phase 2
- Development phase
- 9
- Enrollment target
NCT00397696: Completed Phase 2 study, sponsored by Institute for Neurodegenerative Disorders.
NCT00397696 is a Phase 2 study that has completed, run by Institute for Neurodegenerative Disorders. The registered enrollment target is 9 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00397696, a Phase 2 study, has completed, sponsored by Institute for Neurodegenerative Disorders.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 9 participants
- Enrollment target
Study Summary
The underlying goal of this study is to assess \[123I\] 5-IA and SPECT imaging as a tool to detect nicotinic receptor activity in the brain of PD patients. All study procedures will be conducted at the Institute for Neurodegenerative Disorders (IND) and Molecular NeuroImaging (MNI) in New Haven, CT. Approximately 10 patients with a diagnosis of PD without cognitive changes will be recruited to participate in this study. Patients will be eligible to participate if they have a diagnosis of PD of more than 2 years duration and have no significant cognitive changes.
Primary Outcome
Does \[123I\] 5-IA demonstrate qualitatively decreased radiotracer uptake in cortical regions consistent with a reduction in nicotinic receptor density in PD patients relative to controls?
Interventions
- DRUG [123I] 5-IA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2006-11 |
| Est. Completion | 2012-01 |
| Phase | Phase 2 |
What the finished NCT00397696 record still lists
NCT00397696 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 9 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (93% lower).
The record links to 0 conditions, and to 1 intervention - of which [123I] 5-IA is the first listed.
NCT00397696 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00397696 about?
NCT00397696 is a clinical study titled "Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons Disease". The underlying goal of this study is to assess \[123I\] 5-IA and SPECT imaging as a tool to detect nicotinic receptor activity in the brain of PD patients. All study procedures will be conducted at the Institute for Neurodegenerative Disorders (IND) and Molecular NeuroImaging (MNI) in New Haven, CT....
What is the current status of trial NCT00397696?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 9 participants. The study started on 2006-11. Estimated completion is 2012-01.
What interventions are being tested in trial NCT00397696?
The interventions under investigation include: [123I] 5-IA (DRUG).
Who is sponsoring clinical trial NCT00397696?
This trial is sponsored by Institute for Neurodegenerative Disorders, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00397696's enrollment target sits among peer trials
9 1989th of 2000 higher than 11 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia